Recently, CellsVision, an AI pathology company in which Wondfo holds an equity stake, has published the results of a multicenter clinical study conducted in collaboration with 17 leading medical institutions across China in The Lancet Digital Health (Impact Factor: 24.1).

The study validated the PanCAM pan-cancer lymph node metastasis detection AI model, which covers 33 cancer types. It included 9,256 patients, 69,502 WSIs(Whole Slide Images), and 153,985 lymph node samples. In prospective validation, the model achieved a sensitivity ranging from 0.93 to 1.00.

In the retrospective study, PanCAM additionally identified 4.0% of lymph node metastasis cases that had been missed by pathologists. In the prospective study, it successfully assisted in detecting 21 cases of micro-metastases that are difficult to identify through routine slide review, adding an average of only 13 seconds per patient. These findings further demonstrate the clinical value of AI-assisted diagnosis in improving pathological accuracy and reducing missed diagnoses.
 

From Research Excellence to Clinical Adoption
 

CellsVision has been involved in more than 30 pathology-related research projects, with findings published in leading international journals including The Lancet Oncology, Nature Communications, and The International Journal of Surgery. Among these, two papers each have been published in The Lancet Digital Health and eClinicalMedicine, with a cumulative impact factor exceeding 260 over the past three years. The publication of the PanCAM model marks a transition from single-cancer applications to comprehensive multi-cancer coverage, representing a new stage of maturity for its AI pathology technology.

Currently, CellsVision's AI pathology products have been adopted by numerous medical institutions both in China and internationally, covering over a hundred tertiary hospitals as well as primary healthcare facilities.
 

Building an Integrated AI Pathology Ecosystem
 

Since 2018, Wondfo has been strategically investing in AI healthcare. Through investment in CellsVision, Wondfo is building an integrated pathology solution by combining external innovation with internal capabilities.

CellsVision has developed a comprehensive portfolio of solutions, including digital research platforms, intelligent diagnostic platforms, remote consultation systems, and digital management platforms. Today, CellsVision has been granted 41 patents related to digital pathology.

In terms of hardware compatibility, CellsVision's AI software can seamlessly integrate with mainstream scanning devices. Combined with Wondfo's strengths in pathology hardware, the two parties have established a complete solution covering "digital scanning – AI-assisted diagnosis – reagent support", providing hospitals with flexible one-stop procurement options.
 

Accelerating Global Expansion
 

In collaboration with CellsVision, Wondfo is accelerating the international expansion of AI pathology solutions, achieving initial breakthroughs across multiple regions:

Hong Kong and Macau: CellsVision's AI pathology products have been implemented at Hong Kong Pok Oi Hospital, making it the first Chinese company to introduce AI pathology solutions into Hong Kong.

Europe: The "AI + SaaS" model has been successfully deployed in Italy through collaboration with local pathology laboratories.

Emerging Markets: Joint efforts are underway to expand into markets including South Korea, Vietnam, Russia, Mexico, Turkey, the Philippines, Bangladesh, Thailand, and Indonesia, accelerating global deployment across multiple platforms.

Wondfo will continue to advance its AI pathology strategy. By driving a positive cycle of technological innovation and commercialization, AI pathology is expected to become a key growth driver for Wondfo in the future.